Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Manifest Glaucoma Trial (EMGT)
NCT00000132Phase 3Unknown
- Sponsor
- National Eye Institute
- Start
- Oct 1992
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of betaxolol in open-angle glaucoma (OAG) (2 arms), sponsored by National Eye Institute. Primary endpoint: Glaucoma progression at 4 years. Status: unknown.
02
Drugs
betaxolol
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT00000132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000132.